Melanoma vaccine - Boehringer Ingelheim

Drug Profile

Melanoma vaccine - Boehringer Ingelheim

Alternative Names: BIWB 1; BIWB 2

Latest Information Update: 11 Jun 2002

Price : $50

At a glance

  • Originator Boehringer Ingelheim
  • Class Cancer vaccines; Gene therapies
  • Mechanism of Action Immunostimulants; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Malignant melanoma

Most Recent Events

  • 11 Jun 2002 No development reported - Phase-II for Malignant melanoma in Austria (unspecified route)
  • 17 Aug 2000 A preclinical study has been added to the Cancer pharmacodynamics section
  • 17 Jun 2000 Phase-II clinical trials for Malignant melanoma in Austria (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top